title: Long-term results with MACOP-B in the treatment of aggressive non-Hodgkin's lymphomas. The experience in Brazil.
abstract: From October 1984 to December 1989, 59 patients with aggressive non-Hodgkin's lymphomas (diffuse mixed, diffuse large cell, and immunoblastic) were treated with MACOP-B. All patients were previously untreated and most of them had advanced disease. Complete response (CR) was observed in 66%. Actuarial overall survival, failure-free survival (FFS), and relapse-free survival at 8 years were 54%, 52%, and 81%, respectively, with a median follow-up of 76 months (range: 28-92 months). The presence of B symptoms influenced significantly the CR rate, while FFS was affected by B symptoms, bone marrow involvement, and number of extranodal sites. Toxicity was high, with mucositis grade 2 or 3 occurring in 70%, leukopenia grades 3 or 4 in 80%, and death in 11.8% of the patients. MACOP-B was active in the treatment of aggressive non-Hodgkin's lymphomas, mainly in patients with few poor-prognosis factors, but other less toxic regimens would be more appropriate for this population. For poor-prognosis patients, new therapeutic modalities are necessary.
authors.affiliation: Clinical Oncology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
authors.forename: M A
authors.initials: MA
authors.lastname: Costa
authors.forename: M
authors.initials: M
authors.lastname: Rabinowits
authors.forename: M J
authors.initials: MJ
authors.lastname: Froimtchuk
authors.forename: L O
authors.initials: LO
authors.lastname: Olivatto
authors.forename: S E
authors.initials: SE
authors.lastname: Allan
authors.forename: R A
authors.initials: RA
authors.lastname: Gil
authors.forename: C A
authors.initials: CA
authors.lastname: Andrade
authors.forename: J L
authors.initials: JL
authors.lastname: Martino
authors.forename: J A
authors.initials: JA
authors.lastname: Dobbin
authors.forename: M K
authors.initials: MK
authors.lastname: Carriço
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D001938:Brazil; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D012959:Socioeconomic Factors; D015996:Survival Rate; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate